Terns Pharmaceuticals Inc Total Liabilities
Terns Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Terns Pharmaceuticals Inc (TERN) has total liabilities worth $17.59 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check TERN cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Terns Pharmaceuticals Inc (2018–2024)
Total liabilities of Terns Pharmaceuticals Inc from 2018 to 2024. This chart illustrates how Terns Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Terns Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Terns Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Encounter Resources Ltd
AU:ENR
|
Australia | AU$1.62 Million |
|
Magadh Sugar & Energy Limited
NSE:MAGADSUGAR
|
India | Rs-8.80 Billion |
|
Veracruz Properties SOCIMI SA
MC:YVCP
|
Spain | €41.37 Million |
|
Fortune Mate Indonesia Tbk
JK:FMII
|
Indonesia | Rp54.05 Billion |
|
AXON PARTNERS GRP EO -10
F:XE1
|
Germany | €8.31 Million |
|
Zuari Agro Chemicals Limited
NSE:ZUARI
|
India | Rs15.46 Billion |
|
Sona Topas Tourism Industry
JK:SONA
|
Indonesia | Rp280.21 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Terns Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Terns Pharmaceuticals Inc balance sheet assets.
Liquidity & Leverage Metrics
Terns Pharmaceuticals Inc Total Liabilities Ratios Explained
Terns Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 19.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Terns Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Terns Pharmaceuticals Inc (2018–2024)
The table below shows the annual total liabilities of Terns Pharmaceuticals Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $18.06 Million | +37.33% |
| 2023-12-31 | $13.15 Million | +30.42% |
| 2022-12-31 | $10.08 Million | +29.82% |
| 2021-12-31 | $7.77 Million | -67.23% |
| 2020-12-31 | $23.70 Million | +324.70% |
| 2019-12-31 | $5.58 Million | -66.87% |
| 2018-12-31 | $16.84 Million | -- |
About Terns Pharmaceuticals Inc
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hor… Read more